Dioxygenase mutant and use thereof in synthesis of (2s,3r)-3-hydroxypiperidine acid

Through the enzyme engineering transformation of L-proline-3-hydroxylase, an efficient L-proline-3-hydroxylase mutant R97M/N43T was constructed, which solved the problem of low catalytic efficiency of wild-type and achieved The production of (2S,3R)-3-hydroxypiperidinic acid is efficiently catalyzed, which improves yield and catalytic activity, and solves the environmental and energy consumption problems in traditional synthesis methods.

WO2024245391A1PCT designated stage expired Publication Date: 2024-12-05JIANGNAN UNIV

Patent Information

Application Number
PCT/CN2024/096634
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Wild-type L-proline-3-hydroxylase catalyzed the conversion of L-piperidinic acid to (2S,3R)-3-hydroxypiperidinic acid is low, and traditional synthesis methods have the use of hazardous chemicals and environmental pollution. and the problem of high energy consumption.

Method used

Through the enzyme engineering of L-proline-3-hydroxylase, the 97th arginine in the amino acid sequence is mutated to methionine and combined with different mutations to asparagine at position 43. (such as threonine, alanine, serine, aspartic acid, lysine), a highly efficient L-proline-3-hydroxylase mutant R97M/N43T was constructed to improve its L-piperidine mutant, which increased its response to L-piperidine Catalytic activity of acid.

Benefits of technology

The catalytic activity of the L-proline-3-hydroxylase mutant R97M/N43T and the molar yield of (2S,3R)-3-hydroxypiperidinic acid reached 88%, which was 4.11 times that of the wild type. , and the catalytic yield reached 1278 mg/L under optimized conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024096634_05122024_PF_FP_ABST
    Figure CN2024096634_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a dioxygenase mutant and the use thereof in the synthesis of (2S,3R)-3-hydroxypiperidine acid. Arginine at position 97 and asparagine at position 43 of proline 3-hydroxylase are mutated, wherein the specific activity of R97M / N43T is 2.42 times that of R97M, and is 3.83 times that of a wild type; after conditions are optimized, under the condition of a crude enzyme, when the concentration of the substrate L-piperidine acid is 10 mM, the molar yield of R97M / N43T is 8.82 mM, and the molar yield reaches 88%, which is 4.11 times that of a wild type. At this time, the yield of (2S,3R)-3-hydroxypiperidine acid generated from L-piperidine acid under the catalysis of R97M / N43T is 1278 mg·L-1. The mutant has an improved catalytic efficiency on L-piperidine acid, and is more suitable for use in research on the production of (2S,3R)-3-hydroxypiperidine acid.
Need to check novelty before this filing date? Find Prior Art

Description

Dioxygenase mutants and their applications in the synthesis of (2S,3R)-3-hydroxypiperidinic acid Technical Field

[0001] The invention relates to a dioxygenase mutant and application thereof in synthesizing (2S, 3R)-3-hydroxypiperidinic acid, belonging to the technical fields of enzyme engineering and genetic engineering. Background Art

[0002] Pipecolic acid is a chiral, cyclic, non-protein amino acid and a homologue of proline; it is present in many natural and synthetic bioactive molecules. Its derivative, hydroxypipecolic acid, is widely distributed in nature and found in several antibiotics, terpenoids, and alkaloids. Hydroxypipecolic acid is also an important building block for the synthesis of chiral drugs and other applications. (2S,3R)-3-Hydroxypipecolic acid has been shown to couple with amines to form a precursor of tetrazolamine, which exhibits significant antibacterial activity and potent cytotoxicity against P388 leukemia cells. Furthermore, (2S,3R)-3-Hydroxypipecolic acid has been used as a building block in the biosynthetic pathway of GE81112, which acts as a translation inhibitor to inhibit the formation of the transport initiation complex.

[0003] (2S,3R)-3-Hydroxypiperidinic acid can be synthesized via several methods: racemization followed by enzymatic hydrolysis; and diastereoselective methods, typically using natural or unnatural amino acids (serine and its derivatives, glutamate, or proline), carbohydrates (glyceraldehyde or D-glucose), or optically active α-hydroxycarboxylic acids / 1,2-aminoethanol / sulfoxides as precursors. However, these synthetic processes often involve hazardous and toxic chemicals, resulting in the production of toxic byproducts and environmental concerns. Furthermore, they suffer from poor selectivity and high energy consumption. Enzymatic synthesis, with its high catalytic efficiency, high selectivity, low energy consumption, and environmental friendliness, represents a more viable alternative.

[0004] Reports on the enzymatic production of (2S,3R)-3-hydroxypiperidinic acid are limited. The powerful and versatile biocatalysts of Fe(II) / α-ketoglutarate-dependent dioxygenases make them ideal candidates for industrial production. Notably, only a few enzymes belonging to this family have been identified as catalyzing the conversion of L-piperidinic acid to (2S,3R)-3-hydroxypiperidinic acid, including L-proline-3-hydroxylase from Streptomyces sp. strain TH1; L-proline-4-hydroxylase from Sinorhizobium meliloti; and GetF from Streptomyces sp. L-49973. Although wild-type L-proline-3-hydroxylase can specifically catalyze the conversion of L-piperidinic acid to (2S,3R)-3-hydroxypiperidinic acid, it suffers from low catalytic efficiency. Summary of the Invention

[0005] To address the low catalytic efficiency of the wild-type L-proline-3-hydroxylase in catalyzing the conversion of L-piperidinic acid to (2S,3R)-3-hydroxypiperidinic acid, the present invention uses enzyme engineering to pave the way for improving the reactivity of L-proline-3-hydroxylase toward the non-natural substrate L-piperidinic acid. At a substrate concentration of 10 mM, the molar yield of the wild-type L-proline-3-hydroxylase catalyzing the conversion of L-piperidinic acid to (2S,3R)-3-hydroxypiperidinic acid under crude enzyme conditions was 21.40%. Therefore, enzyme engineering was used to modify the catalytic activity of the L-proline-3-hydroxylase used in the present invention. This increases the number of enzymes capable of efficiently and specifically catalyzing the conversion of L-piperidinic acid to (2S,3R)-3-hydroxypiperidinic acid, bringing new discoveries to the research on enzymatic production of (2S,3R)-3-hydroxypiperidinic acid.

[0006] The present invention provides an L-proline-3-hydroxylase mutant with improved catalytic efficiency for L-piperidic acid. The mutant is obtained by mutating the 97th amino acid of the L-proline-3-hydroxylase whose starting amino acid sequence is shown in SEQ ID NO. 1, and by mutating the 43rd amino acid of the first-round protein engineering forward mutant R97M.

[0007] SEQ ID NO. 1 (amino acid sequence of wild-type L-proline-3-hydroxylase):

[0008] MRSHILGRIELDQERLGRDLEYLATVPTVEEEYDEFSNGFWKNIPLYNASGGSEDRLYRDLEGSPAQPTKHAEQVPYLNEIITTVYNGERLQMARTRNLKNAVVIPHRDFVELDRELDQYFRTHLMLEDSPLAFHSDDDTVIHMR AGEIWFLDAAAVHSAVNFAEFSRQSLCVDLAFDGAFDEKEAFADATVYAPNLSPDVRERKPFTKEREAGILALSGVIGRENFRDILFLLSKVHYTYDVHPGETFEWLVSVSKGAGDDKMVEKAERIRDFAIGARALGERFSLTTW

[0009] The present invention provides an L-proline 3-hydroxylase mutant, which is obtained by mutating the arginine at position 97 and the asparagine at position 43 of the proline 3-hydroxylase whose amino acid sequence is shown in SEQ ID NO. 1.

[0010] In one embodiment of the present invention, the L-proline 3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase as shown in SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to threonine; designated as R97M / N43T (amino acid sequence as shown in SEQ ID NO. 4).

[0011] In one embodiment of the present invention, the L-proline 3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to alanine; designated as R97M / N43A (amino acid sequence as shown in SEQ ID NO. 5).

[0012] In one embodiment of the present invention, the L-proline 3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to valine; designated as R97M / N43V (amino acid sequence as shown in SEQ ID NO. 6).

[0013] In one embodiment of the present invention, the L-proline 3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase as shown in SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to serine; designated as R97M / N43S (amino acid sequence as shown in SEQ ID NO. 7).

[0014] In one embodiment of the present invention, the L-proline 3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase as shown in SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to aspartic acid; it is named R97M / N43D (amino acid sequence as shown in SEQ ID NO. 8).

[0015] In one embodiment of the present invention, the L-proline 3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to lysine; designated as R97M / N43K (amino acid sequence as shown in SEQ ID NO. 9).

[0016] The present invention also provides a gene encoding the L-proline-3-hydroxylase mutant.

[0017] The present invention also provides a recombinant vector carrying the gene according to claim 3.

[0018] In one embodiment of the present invention, the recombinant vector includes but is not limited to: pET-28a.

[0019] The present invention also provides a microbial cell expressing the L-proline-3-hydroxylase mutant or carrying the gene or the recombinant vector.

[0020] In one embodiment of the present invention, the microbial cell is a host cell of Escherichia coli, Bacillus subtilis or yeast.

[0021] In one embodiment of the present invention, the microbial cell is a bacterial or fungal host cell.

[0022] The present invention also provides a method for preparing (2S, 3R)-3-hydroxypiperidinic acid, which comprises adding the L-proline-3-hydroxylase mutant or the microbial cell to a reaction system containing L-piperidinic acid to carry out a reaction to prepare (2S, 3R)-3-hydroxypiperidinic acid.

[0023] In one embodiment of the present invention, the method is to add the L-proline-3-hydroxylase mutant or the microbial cell to a reaction system containing L-piperidinic acid, α-ketoglutaric acid, L-ascorbic acid, and FeSO4·7H2O to react and prepare (2S,3R)-3-hydroxypiperidinic acid.

[0024] In one embodiment of the present invention, crude enzyme (100 μL) is added to a 150 μL reaction system. The final reaction system contains 10 mM of the substrate L-piperidinic acid. The α-ketoglutarate concentration must be greater than 10 mM, and in this case, the concentration can be in the range of 15-30 mM. The L-ascorbic acid concentration must be greater than 0 mM, and in this case, the concentration can be in the range of 10-20 mM. The FeSO₄·7H₂O concentration must be low, and in this case, the concentration can be in the range of 0-0.10 mM. The final reaction mixture volume is 250 μL. The reaction is carried out at 10°C and pH 6.5 for 12 h.

[0025] In one embodiment of the present invention, the reaction conditions are as follows: the crude enzyme (100 μL) is added to the reaction system (150 μL), the final reaction system contains 10 mM substrate L-piperidinic acid, 30 mM α-ketoglutaric acid, 15 mM L-ascorbic acid, 0.05 mM FeSO4·7H2O, and the final reaction mixture volume is 250 μL; the reaction is carried out at 10°C and pH 6.5 for 12 h.

[0026] The present invention also provides a method for improving the catalytic activity of L-proline 3-hydroxylase on the substrate L-piperidic acid, wherein the L-proline 3-hydroxylase mutant is produced by mutating the arginine at position 97 and the asparagine at position 43 of the proline 3-hydroxylase whose amino acid sequence is shown in SEQ ID NO. 1.

[0027] In one embodiment of the present invention, the method is to mutate the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutate the asparagine at position 43 to threonine.

[0028] In one embodiment of the present invention, the method is to mutate the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutate the asparagine at position 43 to alanine.

[0029] In one embodiment of the present invention, the method is to mutate the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutate the asparagine at position 43 to valine.

[0030] In one embodiment of the present invention, the method is to mutate the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutate the asparagine at position 43 to serine.

[0031] In one embodiment of the present invention, the method is to mutate the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutate the asparagine at position 43 to aspartic acid.

[0032] In one embodiment of the present invention, the method is to mutate the arginine at position 97 of the proline 3-hydroxylase as shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutate the asparagine at position 43 to lysine.

[0033] The present invention also provides the use of the above-mentioned L-proline-3-hydroxylase mutant, or the above-mentioned gene, or the above-mentioned recombinant vector, or the above-mentioned recombinant cell in the preparation of (2S, 3R)-3-hydroxypiperidinic acid or a product containing (2S, 3R)-3-hydroxypiperidinic acid; the application is to add the L-proline-3-hydroxylase mutant or the recombinant L-proline-3-hydroxylase mutant expressed by the microbial cell to a reaction system containing L-piperidinic acid for reaction to prepare (2S, 3R)-3-hydroxypiperidinic acid.

[0034] The present invention also provides a method for constructing the above-mentioned L-proline-3-hydroxylase mutant, which comprises the following steps:

[0035] (1) Based on the sequence information of the L-proline 3-hydroxylase gene from Streptomyces sp. strain TH1 published in the NCBI database, codon optimization was performed according to the codon preference rules of Escherichia coli to obtain the optimized L-proline 3-hydroxylase gene, which was then ligated with the expression vector pET28a to construct the L-proline 3-hydroxylase expression vector.

[0036] (2) The gene involved in the site-directed saturation mutagenesis was synthesized by Cerebrolysin, and an expression vector containing the L-proline-3-hydroxylase mutant was prepared.

[0037] (3) The above vectors were transformed into BL21 engineering bacteria by chemical transformation to express the enzyme proteins. The strains were cultured in a test tube at 37°C shaker overnight, and then transferred to a 2% inoculum containing 50 mg·L -1 After culturing in LB liquid medium containing kanamycin at 37°C for 2-2.5 h, IPTG at a concentration of 0.10 mM was added and the temperature was shifted to 17°C for 16 h.

[0038] (4) 8000 r·min -1 After centrifugation for 5 min to collect the cells, the cells were disrupted by ultrasonication at 12000 r·min -1 After centrifugation in a refrigerated centrifuge for 30 minutes, the supernatant was taken and used directly in the crude enzyme reaction to explore the changes in molar yield under crude enzyme conditions. Alternatively, the supernatant was purified by nickel column. The purified L-proline-3-hydroxylase was used to determine its enzymatic properties such as enzyme activity and kinetic parameters. Among them, the enzyme activity was detected by Fmoc-Cl pre-column derivatization method and analyzed by high performance liquid chromatography (HPLC); the kinetic parameters (K m and V max ) was determined in a standard enzyme activity assay system in three steps, and the Michaelis-Menten model was fitted using GraphPad Prism. The final protein concentration was maintained at 0.50 mg mL -1 .

[0039] The present invention provides a method for improving the enzymatic activity of L-proline-3-hydroxylase, wherein the method comprises the following steps: mutating the arginine at position 97 of the proline 3-hydroxylase as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to threonine; or mutating the arginine at position 97 of the proline 3-hydroxylase as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to alanine; or mutating the arginine at position 97 of the proline 3-hydroxylase as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to valine; or mutating the arginine at position 97 of the proline 3-hydroxylase as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to serine; or mutating the arginine at position 97 of the proline 3-hydroxylase as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to serine. .1, the arginine at position 97 of the proline 3-hydroxylase shown in SEQ ID NO.1 is mutated to methionine, and the asparagine at position 43 is mutated to aspartic acid; or the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence shown in SEQ ID NO.1 is mutated to methionine, and the asparagine at position 43 is mutated to lysine. Beneficial effects

[0040] (1) The specific activity of the L-proline-3-hydroxylase mutant R97M / N43T of the present invention is improved. 100 μL of pure enzyme was added to a 150 μL reaction system. The final reaction conditions were: L-piperidinic acid 10 mM, 2-OG 10 mM, Vc 10 mM, FeSO4·7H2O 1 mM, 50 mM MES buffer (pH 6.5); the reaction was carried out on a metal shaker at 17°C and 1000 r·min. -1 The specific activity of R97M / N43T was 0.46 μmol·min after 15 min reaction under the same conditions. -1 mg -1 , which is 2.42 times that of R97M and 3.83 times that of WT.

[0041] (2) The mutant R97M / N43T of the present invention was successfully optimized. The reaction conditions (temperature and pH) and reaction components (Fe 2+ , 2-OG and Vc) concentrations. R97M / N43T under higher temperature, slightly acidic environment and high concentration of Fe 2+ The activity is low under the conditions; the reaction is not completely dependent on exogenous Fe 2+ , but depends on 2-OG; the 2-OG concentration required for the reaction is in excess of the substrate concentration, and the addition of Vc can promote the reaction.

[0042] (3) Under the optimal conditions of 10 mM L-Pip concentration, the molar yield of (2S,3R)-3-hydroxypiperidinic acid catalyzed by R97M / N43T was 88%, which was 4.11 times that of the wild type. At this time, the yield of (2S,3R)-3-hydroxypiperidinic acid catalyzed by R97M / N43T was 1278 mg·L -1 . BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1: Expression verification of the saturation mutant library of N43 using R97M as template; M: protein marker; 1: soluble fraction of E. coli BL21 (DE3); 2: E. coli BL21 / pET28a(+)-R97M (33.15 kDa); 3: R97M / N43G; 4: R97M / N43A; 5: R97M / N43V; 6: R97M / N43L; 7: R97M / N 43I; 8: R97M / N43M; 9: R97M / N43W; 10: R97M / N43F; 11: R97M / N43P; 12: R97M / N43S; 13: R97M / N43T; 14: R97M / N43C; 15: R97M / N43Y; 16: R97M / N43Q; 17: R97M / N43D; 18: R97M / N43E; 19: R97M / N43K; 20: R97M / N43R; 21: R97M / N43H.

[0044] Figure 2: SDS-PAGE electrophoresis results of the purified L-proline 3-hydroxylase mutant; where M is the protein molecular weight standard; 1 is the SDS-PAGE electrophoresis result of the soluble fraction of wild-type L-proline 3-hydroxylase (WT); 2 is the SDS-PAGE electrophoresis result after WT purification; 3 is the SDS-PAGE electrophoresis result of the soluble fraction of the L-proline 3-hydroxylase mutant R97M; 4 is the SDS-PAGE electrophoresis result after R97M purification.

[0045] Figure 3: Catalytic performance of WT and R97M; light-colored columns represent the results under crude enzyme conditions, and the corresponding light-colored y-axis on the left represents the molar yield (%); dark-colored columns represent the results under pure enzyme conditions, and the corresponding dark-colored y-axis represents the enzyme specific activity (μmol·min -1 mg -1 ).

[0046] Figure 4: Effects of reaction conditions temperature and pH on the yield of (2S,3R)-3-hydroxypiperidinic acid.

[0047] Figure 5: Effect of the concentrations of the reaction components FeSO4·7H2O, α-ketoglutaric acid, and L-ascorbic acid on the yield of (2S,3R)-3-hydroxypiperidinic acid.

[0048] Figure 6: Results of iterative mutation of N43 using R97M as template. DETAILED DESCRIPTION

[0049] The culture medium and solution involved in the following examples are as follows:

[0050] LB liquid medium (mg·mL -1 ): yeast extract 5, tryptone 10, NaCl 10.

[0051] LB solid medium (mg·mL -1 ): Yeast extract 5, tryptone 10, NaCl 10, agar powder 15.

[0052] Protein purification solution A: 20 mM Tris-HCl, 150 mM NaCl, adjust the pH to 7.5 and 8.0 with hydrochloric acid.

[0053] Protein purification solution B: 20 ​​mM Tris-HCl, 150 mM NaCl, 1 M imidazole, adjusted to pH 7.5 and 8.0 with hydrochloric acid.

[0054] Low salt buffer: 20 mM Tris-HCl, 100 mM NaCl, adjust pH to 7.5 with hydrochloric acid.

[0055] Protein gel staining solution: To a total volume of 1000 mL of protein gel staining solution, weigh 1 g of Coomassie Brilliant Blue R250, add 450 mL of ethanol, 100 mL of acetic acid, and 450 mL of deionized water, and mix well.

[0056] Protein gel destaining solution: To prepare a total volume of 1000 mL of protein gel staining solution, add 100 mL of ethanol, 100 mL of acetic acid, and 800 mL of deionized water and mix well.

[0057] The detection methods involved in the following embodiments are as follows:

[0058] Detection of (2S,3R)-3-hydroxypiperidinic acid content:

[0059] The sample was aspirated, centrifuged, and the supernatant diluted to 4-7 mM. 125 μL of the sample was then added to 125 μL of 200 mM borate buffer (pH 9.2), followed by 250 μL of 10 mM Fmoc-Cl. The mixture was shaken and allowed to react for 15 min. The reaction was terminated by adding 250 μL of 40 mM 1-aminoadamantane. The sample was filtered through a 0.22 μm organic filter and used for analysis. Detection conditions: A Diomansil C18 column (4.60 mm × 250 mm × 5 μm) was used, with UV detection at 263 nm, a temperature of 25°C, and a flow rate of 1 mL min. -1 The injection volume was 10 µL. A gradient elution method was used, with mobile phase A consisting of 50 mM sodium acetate-glacial acetic acid buffer, pH 4.2; mobile phase B consisting of acetonitrile. The gradient program was: Buffer A: 70% (0-19 min); 20% (19-19.50 min); 0% (19.50-23.50 min); and 70% (23.50-28 min). (2S,5S)-5-hydroxypiperidinic acid has the same molecular weight as (2S,3R)-3-hydroxypiperidinic acid, so the standard solution for quantification was prepared using (2S,5S)-5-hydroxypiperidinic acid.

[0060] Molar yield calculation: When the reaction is performed with 10 mM substrate L-Pip, the theoretical molar yield of the product (2S,3R)-3-hydroxypiperidinic acid is 10 mM. The actual amount of product produced is determined using the (2S,3R)-3-hydroxypiperidinic acid content assay described above. Molar yield (%) = (actual yield / theoretical yield) × 100.

[0061] The preparation method of the competent state involved in the following examples:

[0062] Preparation of competent cells: According to the instructions of the Competent Cell Preparation kit (purchased from TaKaRa), a single colony of E. coli on the non-kanamycin-resistant LB plate was picked into an LB tube and incubated at 37°C and 200 rpm. -1 The cells were cultured overnight for 8-12 hours at 37°C and 200 rpm. The inoculum was then transferred to a 250 mL Erlenmeyer flask containing 50 mL LB medium at a 2% inoculum volume. -1 Cultured to OD 600 After the pH value is about 0.6-0.8, place the flask on ice for 30 min. In a clean bench, divide 50 ml of the bacterial solution into two sterilized 50 ml centrifuge tubes in 25 ml portions. Centrifuge at 6000 r·min at 4°C. -1After centrifugation for 5 min, the supernatant was discarded and 10% A solution was added to gently resuspend the cells. The cells were then centrifuged again at 4°C and 6000 r·min. -1 After centrifugation for 5 minutes, discard the supernatant and gently resuspend the cells in 10% buffer B. Aliquot 100 μL into 1.5 mL sterilized EP tubes and store at -80°C for up to 1 year. Ensure all operations are performed aseptically.

[0063] The chemical conversion methods involved in the following embodiments are:

[0064] Chemical transformation: After thawing the competent medium on ice, add 10 μL of the recombinant plasmid in a clean bench; mix gently and place on ice for about 30 minutes; heat shock in a metal bath at 42°C for 90 seconds and place on ice for 5 minutes; add 800 ml of LB medium and incubate at 37°C, 200 rpm. -1 Incubate for 1 h; 6000 r·min -1 After centrifugation for 5 minutes, discard part of the supernatant in a clean bench; resuspend the bacteria in the remaining culture medium and spread them on kanamycin-resistant plates, and incubate them at 37°C overnight for 12 hours; select colonies for colony PCR verification and send them to a sequencing company for sequencing.

[0065] Example 1: Construction of recombinant bacteria containing L-proline-3-hydroxylase mutants

[0066] The specific steps are as follows:

[0067] (1) Construction of expression vector and recombinant bacteria containing wild-type L-proline-3-hydroxylase (cis-P3H)

[0068] The L-proline 3-hydroxylase sequence (SEQ ID NO. 1) was codon-optimized according to the codon preference of Escherichia coli to obtain the optimized L-proline 3-hydroxylase gene. The gene was then ligated with the expression vector pET28a to construct the L-proline 3-hydroxylase (cis-P3H) expression vector pET28a(+)-cis-P3H, resulting in the wild-type recombinant E. coli BL21 / pET28a(+)-cis-P3H.

[0069] PCR system: 25 μL PrimeSTAR ® MAX DNA Polymerase, 23 μL ddH2O, 1 μL pET28a(+)-cis-P3H, 0.50 μL Primer 1, 0.50 μL Primer 2.

[0070] PCR reaction conditions: 98°C for 30 s, 98°C for 10 s, 55°C for 5 s, and 72°C for 90 s, for a total of 30 cycles.

[0071] (2) Construction of expression vector and recombinant bacteria containing L-proline-3-hydroxylase mutant

[0072] The long and short fragments of the PCR product were ligated using homologous recombinase and then transformed into E. coli BL21 (DE3) competent cells. The specific operation was referred to the above chemical transformation method.

[0073] The primer information for each mutant used in the saturation mutagenesis of N43 ( FIG. 6 ) using R97M as a template is listed below ( Table 1 ).

[0074] Table 1: Primer information for R97M and other mutants using R97M as a template for N43 saturation mutagenesis

[0075] Primer sequences of different mutants pET28a(+)-R97MF: tgaacgtctgcaaatggcgcgtaccatgaacctgaaaaacgctgttgttat (SEQ ID NO.10) R: ataacaacagcgtttttcaggttcatggtacgcgccatttgcagacgttca (SEQ ID NO.11) pET28a(+)-R97M / N43GF: tgagttcagcaacggtttctggaaaggcatcccgctgtacaacgcgagcgg (SEQ ID NO.12) R: ccgctcgcgttgtacagcgggatgcctttccagaaaccgttgctgaactca (SEQ ID NO.13) pET28a(+)-R97M / N43AF: tgagttcagcaacggtttctggaaagcgatcccgctgtacaacgcgagcgg (SEQ ID NO.14) R: ccgctcgcgttgtacagcgggatcgctttccagaaaccgttgctgaactca (SEQ ID NO.15) pET28a(+)-R97M / N43VF: tgagttcagcaacggtttctggaaagttatcccgctgtacaacgcgagcgg (SEQ ID NO.16) R: ccgctcgcgttgtacagcgggataactttccagaaaccgttgctgaactca (SEQ ID NO.17) pET28a(+)-R97M / N43LF: tgagttcagcaacggtttctggaaactgatcccgctgtacaacgcgagcgg (SEQ ID NO.18) R: ccgctcgcgttgtacagcgggatcagtttccagaaaccgttgctgaactca (SEQ ID NO.19) pET28a(+)-R97M / N43IF: gagttcagcaacggtttctggaaaatcatcccgctgtacaacgcgagcggt (SEQ ID NO.20) R: accgctcgcgttgtacagcgggatgattttccagaaaccgttgctgaactc (SEQ ID NO.21)pET28a(+)-R97M / N43MF:gagttcagcaacggtttctggaaaatgatcccgctgtacaacgcgagcggt(SEQ ID NO.22) R:accgctcgcgttgtacagcgggatcattttccagaaaccgttgctgaactc(SEQ ID NO.23)pET28a(+)-R97M / N43WF:tgagttcagcaacggtttctggaaatggatcccgctgtacaacgcgagcgg(SEQ ID NO.24) R:ccgctcgcgttgtacagcgggatccatttccagaaaccgttgctgaactca(SEQ ID NO.25)pET28a(+)-R97M / N43FF:tgagttcagcaacggtttctggaaattcatcccgctgtacaacgcgagcgg(SEQ ID NO.26) R:ccgctcgcgttgtacagcgggatgaatttccagaaaccgttgctgaactca(SEQ ID NO.27)pET28a(+)-R97M / N43PF:tgagttcagcaacggtttctggaaaccgatcccgctgtacaacgcgagcgg(SEQ ID NO.28) R:ccgctcgcgttgtacagcgggatcggtttccagaaaccgttgctgaactca(SEQ ID NO.29)pET28a(+)-R97M / N43SF:gagttcagcaacggtttctggaaaagcatcccgctgtacaacgcgagcggt(SEQ ID NO.30) R:accgctcgcgttgtacagcgggatgcttttccagaaaccgttgctgaactc(SEQ ID NO.31)pET28a(+)-R97M / N43TF:gagttcagcaacggtttctggaaaaccatcccgctgtacaacgcgagcggt(SEQ ID NO.32) R:accgctcgcgttgtacagcgggatggttttccagaaaccgttgctgaactc(SEQ ID NO.33)pET28a(+)-R97M / N43CF:tgagttcagcaacggtttctggaaatgcatcccgctgtacaacgcgagcgg(SEQ ID NO.34) R:ccgctcgcgttgtacagcgggatgcatttccagaaaccgttgctgaactca(SEQ ID NO.35)pET28a(+)-R97M / N43YF:tgagttcagcaacggtttctggaaatacatcccgctgtacaacgcgagcgg(SEQ ID NO.36) R:ccgctcgcgttgtacagcgggatgtatttccagaaaccgttgctgaactca(SEQ ID NO.37)pET28a(+)-R97M / N43QF:tgagttcagcaacggtttctggaaacagatcccgctgtacaacgcgagcgg(SEQ ID NO.38) R:ccgctcgcgttgtacagcgggatctgtttccagaaaccgttgctgaactca(SEQ ID NO.39)pET28a(+)-R97M / N43DF:tgagttcagcaacggtttctggaaagacatcccgctgtacaacgcgagcgg(SEQ ID NO.40) R:ccgctcgcgttgtacagcgggatgtctttccagaaaccgttgctgaactca(SEQ ID NO.41)pET28a(+)-R97M / N43EF:tgagttcagcaacggtttctggaaagaaatcccgctgtacaacgcgagcgg(SEQ ID NO.42) R:ccgctcgcgttgtacagcgggatttctttccagaaaccgttgctgaactca(SEQ ID NO.43)pET28a(+)-R97M / N43KF:agttcagcaacggtttctggaaaaaaatcccgctgtacaacgcgagcggtg(SEQ ID NO.44) R:caccgctcgcgttgtacagcgggatttttttccagaaaccgttgctgaact(SEQ ID NO.45) pET28a(+)-R97M / N43RF:tgagttcagcaacggtttctggaaacgtatcccgctgtacaacgcgagcgg (SEQ ID NO.46) R:ccgctcgcgttgtacagcgggatacgtttccagaaaccgttgctgaactca (SEQ ID NO.47) pET28a(+)-R97M / N43HF:tgagttcagcaacggtttctggaaacacatcccgctgtacaacgcgagcgg (SEQ ID NO.2) R:ccgctcgcgttgtacagcgggatgtgtttccagaaaccgttgctgaactca (SEQ ID NO.3).

[0076] Expression vectors and recombinant bacteria containing different mutants were prepared; the recombinant bacteria were: E. coli BL21 / pET28a(+)-R97M, E. coli BL21 / pET28a(+)-R97M / N43G, E. coli BL21 / pET28a(+)-R97M / N43A, E. coli BL21 / pET28a(+)-R97M / N43V, E. coli BL21 / pET28a(+)-R97M / N43L, E. coli BL21 / pET28a(+)-R97M / N43I, E. coli BL21 / pET28a(+)-R97M / N43M, E. coli BL21 / pET28a(+)-R97M / N43W, E. coli BL21 / pET28a(+)-R97M / N43F, E.coli BL21 / pET28a(+)-R97M / N43P, E.coli BL21 / pET28a(+)-R97M / N43S, E.coli BL21 / pET28a(+)-R97M / N43T, E.coli BL21 / pET28a(+)-R97M / N43C, E.coli BL21 / pET28a(+)-R97M / N43Y, E.coli BL21 / pET28a(+)-R97M / N43Q, E.coli BL21 / pET28a(+)-R97M / N43D, E.coli BL21 / pET28a(+)-R97M / N43E, E.coli BL21 / pET28a(+)-R97M / N43K, E.coli BL21 / pET28a(+)-R97M / N43R, E.coli BL21 / pET28a(+)-R97M / N43H.

[0077] Example 2: Expression and purification of L-proline-3-hydroxylase mutants

[0078] (1) Expression of L-proline-3-hydroxylase mutants

[0079] The recombinant E. coli BL21 / pET28a(+)-cis-P3H containing the original enzyme prepared in Example 1 and the recombinant bacteria containing the mutant were inoculated into 5 mL of kanamycin (50 μg mL -1 ) in LB medium at 37°C and 200 r·min -1 The mixture was cultured for 8-12 h to prepare seed solutions;

[0080] The prepared seed solution was transferred to the inoculum containing 50 μg·mL at a volume fraction of 2%. -1 50 mL LB medium containing kanamycin, 37°C, 200 rpm -1 OD 600 to 0.6-0.8; 0.10 mM IPTG was added and the temperature was changed to 17°C to induce the expression of recombinant protein for 16 h, and fermentation broths were prepared respectively.

[0081] The fermentation broth was heated at 4°C and 8000 r·min. -1 The cells were collected by centrifugation under the appropriate conditions and washed twice with saline for later use. The recombinant cells were resuspended in 20 mM Tris-HCl (pH 7.5) buffer and the cells containing the target plasmid were sonicated using an ultrasonic disruptor at 400 W for 2 s, followed by a 3-s pause. The cell fragments were centrifuged in a refrigerated centrifuge for 15 min to remove cell debris. The centrifugation temperature was set at 4°C and the speed was set at 10,000 rpm. -1 ; Crude enzyme solutions containing different mutants were prepared respectively.

[0082] The results showed that all recombinant proteins could be heterologously expressed in a soluble form. SDS-PAGE analysis of the soluble fractions of the recombinant proteins showed that the bands were consistent with the predicted molecular weight (Figure 1).

[0083] (2) Purification of L-proline-3-hydroxylase mutants

[0084] The recombinant E. coli BL21 / pET28a(+)-cis-P3H containing the original enzyme and the recombinant bacteria containing the mutant obtained in step (1) were resuspended in 20 mM Tris-HCl buffer, pH 7.5, and ultrasonicated using an ultrasonic disruptor at a power of 400 W, working for 2 s and resting for 3 s; the cell disruption solution was refrigerated and centrifuged at a centrifugal temperature of 4°C and a speed of 12000 r·min. -1 The supernatant was filtered through a 0.22 μm water filter membrane after centrifugation for 30 min. The supernatant was purified using an AKTAxpress system purifier, and a 5 ml HisTrap HP purification column was used. The column was rinsed with 20 mL of ethanol and 40 mL of deionized water at 4°C, and then equilibrated with 20 mL of protein purification solution A (150 mM NaCl, 20 mM Tris-HCl, pH 7.5). The cell disruption supernatant was filtered through a 0.22 μm filter membrane and slowly injected into the column. After washing away impurities with elution buffer 1 (80 mM imidazole, 20 mM Tris-HCl, 150 mM NaCl, pH 7.5, i.e., 8% protein purification solution B), the column was eluted with elution buffer 2 (250 mM imidazole, 20 mM Tris-HCl, 150 mM NaCl, pH 7.5). 7.5, i.e. 25% protein purification solution B) to elute the target protein; the target protein eluate was treated with a desalting column and desalting buffer (10 mM Tris, 100 mM NaCl, pH 7.5) to obtain pure protein L-proline-3-hydroxylase.

[0085] Pure enzyme solutions containing different positive mutants ( FIG. 2 ) and wild-type L-proline-3-hydroxylase were prepared.

[0086] Example 3: Enzyme activity determination

[0087] The specific steps are as follows:

[0088] Crude enzyme or purified protein (100 μL) was added to the reaction system (150 μL) to obtain a final reaction mixture volume of 250 μL. The final reaction system contained 10 mM substrate L-piperidinic acid, 10 mM α-ketoglutaric acid, 10 mM L-ascorbic acid, 1 mM FeSO4·7H2O, and 50 mM MES (pH 6.5). The mixture was then heated in a Thermomixer Comfort metal bath at 17°C and 1000 r·min. -1 Incubation.

[0089] The reaction was carried out for 12 hours under crude enzyme conditions and for 15 minutes under pure enzyme conditions. The final protein concentration under pure enzyme conditions was 0.5 mg mL -1 .

[0090] The reaction was terminated by boiling, and the samples were analyzed by high performance liquid chromatography (HPLC). One unit of enzyme activity is defined as the amount of enzyme required to produce 1 μmol of product per minute in a standard enzyme activity assay system.

[0091] The relative enzyme activities of the control R97M and crude enzyme solutions containing different N43 site mutants obtained in Example 2 were tested respectively. The results are shown in Table 2:

[0092] Table 2: Relative enzyme activities of crude enzyme solutions of saturated mutants of N43 based on R97M

[0093] Enzyme relative activity% Enzyme relative activity% R97M100.00 R97M / N43S236.05 R97M / N43G14.76 R97M / N43T286.65 R97M / N43A212.40 R97M / N43C74.11 R97M / N43V108.34 R97M / N43Y13.11 R97M / N43L14.38 R97M / N43 Q29.14R97M / N43I11.24R97M / N43D121.08R97M / N43M27.09R97M / N43E28.53R97M / N43W0 .00R97M / N43K142.34R97M / N43F6.14R97M / N43R23.73R97M / N43P33.17R97M / N43H47.01

[0094] R97M was set as 100% as a control to calculate the relative enzyme activity of each mutant. As shown in Table 2, the saturation mutation results of N43 using R97M as a template have six positive mutants, namely R97M / N43A, R97M / N43V, R97M / N43S, R97M / N43T, R97M / N43D, and R97M / N43K, with relative enzyme activities of 212.40%, 108.34%, 236.05%, 286.65%, 121.08%, and 142.34%, respectively, and are 2.12, 1.08, 2.36, 2.86, 1.21, and 1.42 times that of R97M, respectively. The investigation of the specific enzyme activity of the six positive mutants at the pure enzyme level is embodied in Example 5.

[0095] Example 4: Comparison of catalytic performance between mutant R97M and wild type WT

[0096] (1) Molar yield (%)

[0097] The crude R97M enzyme solution and the wild-type WT crude enzyme solution (100 μL) prepared in Example 2 were added to the reaction system (150 μL). The final reaction system contained 10 mM substrate L-piperidinic acid, 10 mM α-ketoglutaric acid, 10 mM L-ascorbic acid, 1 mM FeSO4·7H2O, and 50 mM MES (pH 6.5). The reaction was carried out at 17°C for 12 h. The reaction was terminated by boiling, and the samples after the reaction were analyzed by high-performance liquid chromatography (HPLC). The amount of product (2S,3R)-3-hydroxypiperidinic acid produced was detected and the corresponding molar yield was calculated.

[0098] As shown in the blue column in Figure 3, compared with the wild type, the molar yield of the L-proline-3-hydroxylase mutant R97M under the enzyme activity assay conditions reached 36%, which is 1.68 times that of the wild type.

[0099] (2) Specific activity μmol·min -1 mg -1

[0100] The R97M pure enzyme and wild-type WT pure enzyme (100 μL) prepared in Example 2 were added to a 150 μL reaction system. The final reaction system contained 10 mM substrate L-piperidinic acid, 10 mM α-ketoglutaric acid, 10 mM L-ascorbic acid, 1 mM FeSO4·7H2O, and 50 mM MES (pH 6.5). The reaction was carried out at 17°C for 15 min. The final protein concentration of the pure enzyme was maintained at 0.50 mg·ml. -1 The reaction was terminated by boiling, and the sample was analyzed by high performance liquid chromatography (HPLC). The amount of product generated was determined using the (2S,3R)-3-hydroxypiperidinic acid assay described above, and the corresponding specific activity was calculated.

[0101] As shown in the red column in Figure 3, compared with the wild type, the specific activity of the L-proline-3-hydroxylase mutant R97M under the enzyme activity assay conditions was 0.19 μmol·min -1 mg -1 , which is 1.58 times that of the wild type.

[0102] (3) Kinetic parameters

[0103] The kinetic parameters (K) were determined using a final volume of 250 μL of the reaction mixture as a sample. m and V maxFor the substrate, L-pipecolic acid, the concentration range for L-pipecolic acid under standard enzyme activity assay conditions was 0.30 to 25 mM. Similarly, the concentration range for 2-OG was 0.30 to 40 mM. The assay was performed in triplicate, and the Michaelis-Menten model was fitted using GraphPad Prism. The results are shown in Table 3 below.

[0104] Table 3: Kinetic parameters of wild-type L-proline-3-hydroxylase and its mutant R97M. R97M was used as the control and set at 100%, and the relative enzyme activities of each mutant were calculated. As shown in Table 2, saturation mutagenesis of N43 using R97M as a template resulted in six positive mutants: R97M / N43A, R97M / N43V, R97M / N43S, R97M / N43T, R97M / N43D, and R97M / N43K. Their relative enzyme activities were 212.40%, 108.34%, 236.05%, 286.65%, 121.08%, and 142.34%, respectively, representing 2.12, 1.08, 2.36, 2.86, 1.21, and 1.42 times those of R97M, respectively. The specific enzyme activities of these six positive mutants at the pure enzyme level are examined in Example 5.

[0105] Example 4: Comparison of catalytic performance between mutant R97M and wild type WT

[0106] (1) Molar yield (%)

[0107] The crude R97M enzyme solution and the wild-type WT crude enzyme solution (100 μL) prepared in Example 2 were added to the reaction system (150 μL). The final reaction system contained 10 mM substrate L-piperidinic acid, 10 mM α-ketoglutaric acid, 10 mM L-ascorbic acid, 1 mM FeSO4·7H2O, and 50 mM MES (pH 6.5). The reaction was carried out at 17°C for 12 h. The reaction was terminated by boiling, and the samples after the reaction were analyzed by high-performance liquid chromatography (HPLC). The amount of product (2S,3R)-3-hydroxypiperidinic acid produced was detected and the corresponding molar yield was calculated.

[0108] As shown in the blue column in Figure 3, compared with the wild type, the molar yield of the L-proline-3-hydroxylase mutant R97M under the enzyme activity assay conditions reached 36%, which is 1.68 times that of the wild type.

[0109] (2) Specific activity μmol·min -1 mg -1

[0110] The R97M pure enzyme and wild-type WT pure enzyme (100 μL) prepared in Example 2 were added to a 150 μL reaction system. The final reaction system contained 10 mM substrate L-piperidinic acid, 10 mM α-ketoglutaric acid, 10 mM L-ascorbic acid, 1 mM FeSO4·7H2O, and 50 mM MES (pH 6.5). The reaction was carried out at 17°C for 15 min. The final protein concentration of the pure enzyme was maintained at 0.50 mg·ml. -1 The reaction was terminated by boiling, and the sample was analyzed by high performance liquid chromatography (HPLC). The amount of product generated was determined using the (2S,3R)-3-hydroxypiperidinic acid assay described above, and the corresponding specific activity was calculated.

[0111] As shown in the red column in Figure 3, compared with the wild type, the specific activity of the L-proline-3-hydroxylase mutant R97M under the enzyme activity assay conditions was 0.19 μmol·min -1 mg -1 , which is 1.58 times that of the wild type.

[0112] (3) Kinetic parameters

[0113] The kinetic parameters (K) were determined using a final volume of 250 μL of the reaction mixture as a sample. m and V max For the substrate, L-pipecolic acid, the concentration range for L-pipecolic acid under standard enzyme activity assay conditions was 0.30 to 25 mM. Similarly, the concentration range for 2-OG was 0.30 to 40 mM. The assay was performed in triplicate, and the Michaelis-Menten model was fitted using GraphPad Prism. The results are shown in Table 3 below.

[0114] Table 3: Kinetic parameters of wild-type L-proline-3-hydroxylase and its mutant R97M

[0115]

[0116] The results showed that R97M catalyzed the hydroxylation of L-piperidinic acid. m The value (6.83 mM) was lower than that of WT (10.27 mM), indicating that the affinity of R97M for the substrate L-Pip was improved. cat / K m (2.09 min -1 mM -1 ) is WT (1.14 min -1 mM -1 ) is 1.83 times.

[0117] Example 5: Comparison of catalytic performance of positive mutants from R97M and N43 mutation libraries

[0118] The six positive mutants R97M / N43A, R97M / N43V, R97M / N43S, R97M / N43T, R97M / N43D and R97M / N43K obtained in Example 3 were further studied and purified according to the purification procedure described in Example 2. The specific activity was measured in μmol·min -1 mg -1 The specific steps are as follows:

[0119] 100 μL of each of the wild-type, R97M / N43A, R97M / N43V, R97M / N43S, R97M / N43T, R97M / N43D, and R97M / N43K enzymes was added to a 150 μL reaction system containing 10 mM substrate L-piperidinic acid, 10 mM α-ketoglutarate, 10 mM L-ascorbic acid, 1 mM FeSO₄·7H₂O, and 50 mM MES (pH 6.5). The reaction was allowed to proceed at 17°C for 15 min, terminated by boiling, and samples were analyzed by high-performance liquid chromatography (HPLC). The amount of (2S,3R)-3-hydroxypiperidinic acid produced was determined using the method described above, and the corresponding specific activity was calculated. The results are shown in Table 4. Final protein concentration = initial protein concentration ÷ molar extinction coefficient × dilution factor.

[0120] Table 4: Specific activity of pure enzyme solution of positive mutant of N43 based on R97M

[0121] Final enzyme protein concentration mg·mL -1 Specific activity μmol·min -1 mg -1 cis-P3H(WT)0.560.12R97M0.550.19R97M / N43A0.500.45R97M / N43V0.480.24R 97M / N43S0.430.34R97M / N43T0.370.46R97M / N43D0.430.32R97M / N43K0.690.21

[0122] The results showed that the specific activities of R97M / N43A, R97M / N43V, R97M / N43S, R97M / N43T, R97M / N43D, and R97M / N43K were 2.37, 1.26, 1.79, 2.42, 1.68, and 1.11 times that of R97M, and 3.75, 0.20, 2.83, 3.83, 2.67, and 1.75 times that of the wild type, respectively. This indicates that R97M / N43T and R97M / N43A are both dominant mutants, with a specific activity of 0.46 μmol·min -1 mg -1 , 0.45 μmol·min -1 mg -1 , the following experiment only takes R97M / N43T as an example.

[0123] Example 6: Condition Optimization for Mutant R97M / N43T

[0124] (1) Effect of reaction conditions on the yield of (2S,3R)-3-hydroxypiperidinic acid

[0125] 1) Temperature optimization

[0126] The crude R97M / N43T enzyme (100 μL) prepared in Example 2 was added to the reaction system (150 μL). That is, the crude R97M / N43T enzyme (100 μL) was added to the reaction system (150 μL). The final reaction mixture contained 10 mM substrate L-piperidinic acid, 10 mM α-ketoglutaric acid, 10 mM L-ascorbic acid, 1 mM FeSO4·7H2O, and 50 mM MES (pH 6.5). The final reaction mixture volume was 250 μL. The reaction was carried out at 10°C, 17°C, 25°C, 30°C, 37°C, 45°C, and 55°C for 12 h. The results are shown in FIG4 .

[0127] The results showed that the yield of (2S,3R)-3-hydroxypiperidinic acid was the highest when the reaction temperature was 10°C. The yield of (2S,3R)-3-hydroxypiperidinic acid at the reaction temperature of 10-37°C was much higher than that at the reaction temperature of 45 / 55°C.

[0128] 2) pH optimization

[0129] The crude R97M / N43T enzyme (100 μL) prepared in Example 2 was added to the reaction system (150 μL), i.e., the crude enzyme (100 μL) was added to the reaction system (150 μL). The final reaction system contained 10 mM substrate L-piperidinic acid, 10 mM α-ketoglutaric acid, 10 mM L-ascorbic acid, and 1 mM FeSO4·7H2O. The pH of the reaction system was set to 5.5, 6, 6.5, and 7 (MES buffer) and 7, 7.5, 8, 8.5, and 9 (Tris-HCl buffer), respectively. The final reaction mixture volume was 250 μL. The reaction was carried out at 17°C for 12 h. The results are shown in Figure 4.

[0130] The results showed that the yield of (2S,3R)-3-hydroxypiperidinic acid was the highest at pH 7.5, and the yield of (2S,3R)-3-hydroxypiperidinic acid was similar at pH 7.0-9.0, and was higher than that at pH 5.5-6.5.

[0131] (2) Effect of reaction components on the yield of (2S,3R)-3-hydroxypiperidinic acid

[0132] The specific method is the same as step (1), the crude R97M / N43T enzyme (100 μL) prepared in Example 2 was added to the reaction system (150 μL), and the reaction was carried out at 17°C for 12 h. The difference is that 1) the Fe content in the final reaction system was adjusted. 2+ The concentrations of the products were as follows: 1) the concentrations of α-ketoglutarate (2-OG) were adjusted to 0 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, and 40 mM, respectively; 2) the concentrations of L-ascorbic acid (Vc) were adjusted to 0 mM, 2 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, and 30 mM, respectively. The other conditions were the same as those described in Example 3.

[0133] The results are shown in Figure 5. R97M / N43T are respectively 2+ The highest yield was achieved when the concentration was 0.05 mM, the 2-OG concentration was 30 mM, and the Vc concentration was 15 mM. 2+ The yield of (2S,3R)-3-hydroxypiperidinic acid at the concentration of 0-0.5 mM is much greater than that at the concentration of 1-4 mM. 2+ Less tolerant, high Fe 2+ The concentration has a significant negative impact on its catalytic activity. 2+The dependence is not absolute, probably because it combines with endogenous Fe 2+ The yield of (2S,3R)-3-hydroxypiperidinic acid at 2-OG concentrations between 15 and 40 mM was similar and much greater than that at 0 to 10 mM. At this time, the substrate concentration was 10 mM, so the amount of 2-OG added only needed to be greater than the substrate concentration. At the same time, no product was detected at a 2-OG concentration of 0 mM, indicating an absolute dependence on 2-OG. The yield of (2S,3R)-3-hydroxypiperidinic acid at Vc concentrations between 2 and 30 mM was similar and much greater than that at 0 mM. Therefore, the addition of the antioxidant Vc promoted the reaction to a certain extent.

[0134] (3) Molar yield of (2S,3R)-3-hydroxypiperidinic acid catalyzed by R97M / N43T under optimal conditions

[0135] According to the results of the optimization of the above (1) and (2) conditions, the optimized conditions are:

[0136] The crude R97M / N43T enzyme (100 μL) prepared in Example 2 was added to the reaction system (150 μL). That is, the crude enzyme (100 μL) was added to the reaction system (150 μL). The final reaction system contained 10 mM substrate L-piperidinic acid, 30 mM α-ketoglutaric acid, 15 mM L-ascorbic acid, and 0.05 mM FeSO4·7H2O. The final reaction mixture volume was 250 μL. The reaction was carried out at 10°C and pH 6.5 for 12 h.

[0137] Meanwhile, the wild type was used as a control.

[0138] The yield of (2S,3R)-3-hydroxypiperidinic acid was used as the evaluation standard. The results showed that under crude enzyme conditions, at a substrate concentration of 10 mM, the molar yield of R97M / N43T was 8.82 mM, with a molar yield of 88%. Almost no substrate peak was detected, which was similar to the wild type (under the initial reaction conditions described in Example 4 (1), the molar yield was 21.40%, and the yield of (2S,3R)-3-hydroxypiperidinic acid was 310 mg·L -1 The yield of (2S,3R)-3-hydroxypiperidinic acid catalyzed by R97M / N43T was 1278 mg·L -1 .

[0139] Although the present invention has been disclosed above in terms of preferred embodiments, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A L-proline-3-hydroxylase mutant, characterized in that: The L-proline-3-hydroxylase mutant is obtained by simultaneously mutating the arginine at position 97 and the asparagine at position 43 of the proline 3-hydroxylase whose amino acid sequence is shown in SEQ ID NO.1; The L-proline-3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase shown in the amino acid sequence of SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to threonine; Or the L-proline-3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase with an amino acid sequence as shown in SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to alanine; Or the L-proline-3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase with an amino acid sequence as shown in SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to valine; Or the L-proline-3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase with an amino acid sequence as shown in SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to serine; Or the L-proline-3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase with an amino acid sequence as shown in SEQ ID NO. 1 to methionine, and simultaneously mutating the asparagine at position 43 to aspartic acid; Or the L-proline-3-hydroxylase mutant is obtained by mutating the arginine at position 97 of the proline 3-hydroxylase with an amino acid sequence as shown in SEQ ID NO.1 to methionine, and simultaneously mutating the asparagine at position 43 to lysine.

2. A gene encoding the L-proline-3-hydroxylase mutant according to claim 1.

3. A recombinant vector carrying the gene according to claim 2.

4. The recombinant vector according to claim 3, characterized in that The recombinant vector uses pET-28a as an expression vector.

5. A microbial cell expressing the L-proline-3-hydroxylase mutant according to claim 1 or carrying the gene according to claim 2 or carrying the recombinant vector according to claim 3 or 4.

6. The microbial cell according to claim 5, characterized in that The microbial cells are bacteria or fungi as host cells.

7. The microbial cell according to claim 5, characterized in that The microbial cells are Escherichia coli, Bacillus subtilis or yeast as host cells.

8. A method for preparing (2S, 3R)-3-hydroxypiperidinic acid, characterized in that: The method comprises adding the L-proline-3-hydroxylase mutant according to claim 1 or the microbial cell according to any one of claims 5 to 7 to a reaction system containing L-piperidinic acid to carry out a reaction, thereby preparing (2S, 3R)-3-hydroxypiperidinic acid.

9. The preparation method according to claim 8, characterized in that: The method comprises the following steps: adding the L-proline-3-hydroxylase mutant or the microbial cell to a reaction system containing L-piperidinic acid, α-ketoglutaric acid, L-ascorbic acid and FeSO4·7H2O to carry out a reaction to prepare (2S, 3R)-3-hydroxypiperidinic acid.

10. The preparation method according to claim 8, characterized in that: The method comprises the following steps: adding the mutant crude enzyme (100 μL) into a reaction system (150 μL); the final reaction system contains 10 mM substrate L-piperidinic acid; the concentration of α-ketoglutaric acid is 15-30 mM; the concentration of L-ascorbic acid is 10-20 mM; the concentration of FeSO4·7H2O is 0-0.10 mM; the volume of the final reaction mixture is 250 μL; and the reaction is carried out at 10°C and pH 6.5 for 12 h.

11. The preparation method according to claim 8, characterized in that: The method comprises the following steps: adding the mutant crude enzyme (100 μL) to a reaction system (150 μL); the final reaction system contains 10 mM substrate L-piperidinic acid, 30 mM α-ketoglutaric acid, 15 mM L-ascorbic acid, and 0.05 mM FeSO4·7H2O; and the final reaction mixture volume is 250 μL; and reacting for 12 h at 10°C and pH 6.

5.

12. A method for improving the catalytic activity of L-proline-3-hydroxylase on substrate L-piperidinic acid, characterized in that: The method comprises the following steps: mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to threonine; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to alanine; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to valine; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to serine; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to aspartic acid; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to aspartic acid; The arginine at position 97 of the proline 3-hydroxylase shown in NO. 1 is mutated to methionine, and the asparagine at position 43 is mutated to lysine.

13. A method for improving the enzymatic activity of L-proline-3-hydroxylase, characterized in that: The method comprises the following steps: mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to threonine; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to alanine; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to valine; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to serine; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to aspartic acid; or mutating the arginine at position 97 of the proline 3-hydroxylase of the amino acid sequence as shown in SEQ ID NO.1 to methionine, and mutating the asparagine at position 43 to aspartic acid; The arginine at position 97 of the proline 3-hydroxylase shown in NO. 1 is mutated to methionine, and the asparagine at position 43 is mutated to lysine.

14. Use of the L-proline-3-hydroxylase mutant according to claim 1, or the gene according to claim 2, or the recombinant vector according to claim 3 or 4, or the microbial cell according to any one of claims 5 to 7 in the preparation of (2S, 3R)-3-hydroxypiperidinic acid or a product containing (2S, 3R)-3-hydroxypiperidinic acid, characterized in that: The application is to add the L-proline-3-hydroxylase mutant or the recombinant L-proline-3-hydroxylase mutant expressed by the microbial cell to a reaction system containing L-piperidinic acid to carry out a reaction to prepare (2S, 3R)-3-hydroxypiperidinic acid.

Citation Information

Patent Citations

  • Dioxygenase mutant and application thereof in synthesis of (2S, 3R)-3-hydroxypiperidine acid

    CN116656634A

  • Proline hydroxylase and uses thereof

    US20200199544A1

Cited By

  • Dioxygenase mutant and application thereof in synthesis of (2S, 3R)-3-hydroxypiperidine acid

    CN116656634A